Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
Primary Objective: To demonstrate the non-inferiority of Sotagliflozin 400 milligrams (mg) compared to Glimepiride on hemoglobin A1c (HbA1c) reduction at Week 52 in participants with Type 2 Diabetes (T2D) who have inadequate…
- Trial name
- SOTA-GLIM (NCT03332771)
- Testing
- Sotagliflozin (SAR439954), Glimepiride, Metformin
- Where
- 142 sites in United States, Bulgaria and 2 more
- Volunteers
- 954 people
- Sponsor
- Lexicon Pharmaceuticals
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen
Type 2 Diabetes Mellitus
A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment
The primary objective of this study is to compare the pharmacokinetics of ASP1941 in type 2 diabetes mellitus patients with normal renal function and those with mild or moderate renal impairment.
- Trial name
- NCT01097681
- Testing
- ASP1941
- Where
- 2 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes Mellitus
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Primary Objective: To evaluate the efficacy of fixed dose combination of glimepiride and metformin (AMARYL M 1/250mg) in comparison with glimepiride (AMARYL) alone in terms of glycemic control as reflected by HbA1c during a…
- Trial name
- NCT01457911
- Testing
- Glimepiride and Metformin hydrochloride combination (HOE490), Glimepiride (HOE490)
- Where
- 22 sites in China
- Volunteers
- 244 people
- Sponsor
- Sanofi
Acute Liver Injury
Acute Liver Injury in Patients on Dapagliflozin
To compare, by insulin use at the index date, the incidence of hospitalization for acute liver injury (ALI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of…
- Trial name
- NCT02695095
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 424,091 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus, Hypercholesterolemia
Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.
This is a 16-week double-blind, placebo-controlled (for colesevelam hydrochloride (HCl)) study in the type 2 diabetic subjects and pre-diabetic subjects.
- Conditions
- Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
- Trial name
- NCT00570739
- Testing
- Metformin HCl tablets and Colesevelam tablets, Colesevelam
- Where
- 31 sites in United States, Colombia and 2 more
- Volunteers
- 502 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
Initial Combination With Pioglitazone Study (0431-064)
A clinical study to evaluate the safety and efficacy of the initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes mellitus not on treatment with insulin or oral antihyperglycemic therapy.
- Trial name
- NCT00397631
- Testing
- sitagliptin 100 mg q.d./pioglitazone 30 mg q.d
- Volunteers
- 520 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)
In this observational study, data from the recent past of patients with type 2 diabetes mellitus and chronic kidney disease will be studied.
- Trial name
- CKD-T2DM (NCT05004428)
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 336,376 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Glucose Reduction by Early Acarbose Treatment in Basal Insulin
The purpose of this study is to evaluate the efficacy and safety of acarbose in comparison with voglibose in type 2 diabetic patients whose blood glucose levels were inadequately controlled with insulin glargine alone or in…
- Trial name
- GREAN (NCT00970528)
- Testing
- Acarbose (Glucobay, BAYG5421), Voglibose (Basen)
- Where
- 11 sites in South Korea
- Volunteers
- 124 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
This is an 80-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not…
- Trial name
- NCT00138619
- Testing
- vildagliptin
- Where
- 2 sites in United States, Germany
- Volunteers
- 478 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with thiazolidinedione (pioglitazone) in patients with type 2 Diabetes for 12 weeks administration and to evaluate the…
- Trial name
- NCT01026194
- Testing
- Teneli / Teneli + pio
- Where
- Japan
- Volunteers
- 204 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus
Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in Type 2 Diabetes subjects.
- Trial name
- NCT00763022
- Testing
- TAK-559
- Volunteers
- 302 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2, Metabolic Syndrome
MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)
This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome. This is an early phase trial and some specific protocol information is in progress and not publicly…
- Trial name
- NCT00543595
- Testing
- MK0916
- Volunteers
- 154 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)
The purpose of this study is to compare the effects of 2.0 mg exenatide once weekly and insulin glargine, titrated to glucose targets using the algorithm described by Yki- Järvinen et al.(2007), with respect to glycemic…
- Trial name
- NCT00641056
- Testing
- Exenatide Once Weekly, Insulin Glargine
- Where
- 75 sites in United States, Australia and 14 more
- Volunteers
- 467 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- AMPLITUDE-S (NCT03770728)
- Testing
- Efpeglenatide SAR439977, Background therapy: Metformin alone or in combination with SU
- Where
- 48 sites in United States, China and 1 more
- Volunteers
- 312 people
- Sponsor
- Sanofi
Type 2 Diabetes
Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes
This study compared the pharmacokinetic and pharmacodynamic properties of an oral insulin formulation with that of a standard subcutaneous injection of regular human insulin.
- Trial name
- NCT00982254
- Testing
- Oral insulin, regular human insulin
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetes Mellitus, Type 2
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia
The purpose of the study is to collect information on how Tresiba® works in real world patients. Patients will get Tresiba® as prescribed to them by their study doctor. The study will last for about 6 to 8 months.
- Trial name
- UPDATES (NCT03785522)
- Testing
- Insulin degludec
- Where
- 21 sites in Saudi Arabia
- Volunteers
- 597 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study Of BRL49653C For The Treatment Of Type 2 Diabetes
This study is designed to evaluate the safety of BRL49653C administrated for 52 weeks
- Trial name
- NCT00523913
- Testing
- rosiglitazone
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus
The purpose of this study is to assess the safety and effectiveness of three doses of CKD-501 compared to placebo in lowering fasting plasma glucose levels in people with type 2 diabetes for 8 weeks.
- Trial name
- NCT01030679
- Testing
- CKD-501 0.5mg, CKD-501 1mg, CKD-501 2mg
- Where
- 8 sites in South Korea
- Volunteers
- 214 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
This study will assess the effect of LCQ when added to metformin.
- Trial name
- NCT00901979
- Testing
- LCQ908A, Sitagliptin, metformin
- Where
- 67 sites in United States, Canada and 3 more
- Volunteers
- 693 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.